DK1148875T3 - Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer - Google Patents

Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer

Info

Publication number
DK1148875T3
DK1148875T3 DK00903441T DK00903441T DK1148875T3 DK 1148875 T3 DK1148875 T3 DK 1148875T3 DK 00903441 T DK00903441 T DK 00903441T DK 00903441 T DK00903441 T DK 00903441T DK 1148875 T3 DK1148875 T3 DK 1148875T3
Authority
DK
Denmark
Prior art keywords
compositions
increasing
methods
blood cells
white blood
Prior art date
Application number
DK00903441T
Other languages
English (en)
Inventor
Ronald Trevor Macfarland
Andrew W Miller
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of DK1148875T3 publication Critical patent/DK1148875T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00903441T 1999-02-02 2000-02-02 Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer DK1148875T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11825599P 1999-02-02 1999-02-02
EP00903441A EP1148875B1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
PCT/CA2000/000104 WO2000045814A1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count

Publications (1)

Publication Number Publication Date
DK1148875T3 true DK1148875T3 (da) 2004-10-18

Family

ID=22377471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00903441T DK1148875T3 (da) 1999-02-02 2000-02-02 Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer

Country Status (24)

Country Link
US (2) US6365583B1 (da)
EP (1) EP1148875B1 (da)
JP (2) JP4968868B2 (da)
KR (1) KR100643553B1 (da)
CN (1) CN1310642C (da)
AP (1) AP1497A (da)
AT (1) ATE268597T1 (da)
AU (2) AU772979B2 (da)
BR (1) BR0007924A (da)
CA (1) CA2361587C (da)
CZ (1) CZ20012698A3 (da)
DE (1) DE60011391T2 (da)
DK (1) DK1148875T3 (da)
ES (1) ES2222174T3 (da)
HK (1) HK1038319B (da)
HU (1) HUP0200100A3 (da)
IL (1) IL144400A (da)
MX (1) MXPA01007801A (da)
NO (1) NO20013770L (da)
NZ (1) NZ513602A (da)
PT (1) PT1148875E (da)
SI (1) SI1148875T1 (da)
TR (1) TR200102239T2 (da)
WO (1) WO2000045814A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
EP1244648B1 (en) * 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
KR20030034184A (ko) 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
NZ524421A (en) * 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
ES2320323T3 (es) 2000-09-29 2009-05-21 Anormed Inc. Procedimiento para la preparacion de poliamidas ciclicas con proteccion n-1 que contienen atomos de nitrogeno en forma de anillo n, y producto asi obtenido.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
EP1487795B1 (en) 2001-09-12 2010-11-03 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
CA2520259A1 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
RU2005136224A (ru) 2003-04-22 2006-06-10 Анормед Инк. (Ca) Гетероциклические соединения, связывающиеся с рецепторами хемокинов и обладающие повышенной эффективностью
US7491735B2 (en) * 2003-12-11 2009-02-17 Genzyme Corporation Chemokine receptor binding compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆/幹細胞を動員するためのケモカインの組み合わせ
CA2612325A1 (en) * 2005-06-15 2006-12-28 Anormed Inc. Chemokine receptor binding compounds
JP2009504769A (ja) * 2005-08-16 2009-02-05 ジェンザイム・コーポレーション ケモカイン受容体結合化合物
AU2006340074A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
JP2009545620A (ja) * 2006-08-02 2009-12-24 ジェンザイム・コーポレーション 併用療法
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2638802C2 (ru) * 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN109187337A (zh) * 2018-09-10 2019-01-11 南京工业职业技术学院 一种筛选强韧性FeAl晶界的方法
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
EP1133291B1 (en) * 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia

Also Published As

Publication number Publication date
CA2361587A1 (en) 2000-08-10
JP2002536329A (ja) 2002-10-29
CN1310642C (zh) 2007-04-18
BR0007924A (pt) 2001-11-06
US6670354B2 (en) 2003-12-30
PT1148875E (pt) 2004-10-29
DE60011391D1 (de) 2004-07-15
AU772979B2 (en) 2004-05-13
AU2004203847B2 (en) 2007-03-22
ATE268597T1 (de) 2004-06-15
HK1038319B (en) 2005-03-18
EP1148875B1 (en) 2004-06-09
AP1497A (en) 2005-11-20
CA2361587C (en) 2010-04-20
AU2004203847A1 (en) 2004-09-09
MXPA01007801A (es) 2003-06-04
CZ20012698A3 (cs) 2002-03-13
KR100643553B1 (ko) 2006-11-10
JP2011088937A (ja) 2011-05-06
AU2527800A (en) 2000-08-25
HK1038319A1 (en) 2002-03-15
US20020058653A1 (en) 2002-05-16
AP2001002221A0 (en) 2001-09-30
KR20010101896A (ko) 2001-11-15
NZ513602A (en) 2003-10-31
WO2000045814A1 (en) 2000-08-10
SI1148875T1 (en) 2004-12-31
NO20013770D0 (no) 2001-08-01
IL144400A (en) 2010-05-17
NO20013770L (no) 2001-09-27
EP1148875A1 (en) 2001-10-31
US6365583B1 (en) 2002-04-02
IL144400A0 (en) 2002-05-23
HUP0200100A2 (hu) 2002-05-29
HUP0200100A3 (en) 2004-07-28
CN1338933A (zh) 2002-03-06
ES2222174T3 (es) 2005-02-01
TR200102239T2 (tr) 2002-01-21
DE60011391T2 (de) 2005-07-14
JP4968868B2 (ja) 2012-07-04

Similar Documents

Publication Publication Date Title
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DK0958838T3 (da) Fremgangsmåde til fjernelse af hvide blodlegemer
DK0971735T3 (da) Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
NO20013770D0 (no) Metoder og blandinger for å öke antall hvite blodceller
NO20013393L (no) Bronnsementeringsfremgangsmater og sammensetninger
NO20000847D0 (no) Elastiske brønnsementsammensetninger og fremgangsmåter
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
NO20005828L (no) Herdbare punktfluidsammensetninger og fremgangsmåter
ATE388677T1 (de) Zwischenwirbelimplantat
ATE357459T1 (de) Antikörper gegen mensliches il-12
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
FR2780269B1 (fr) Implant rachidien
DE60130586D1 (de) Speicherzelle
DK1360287T3 (da) Fremgangsmåder til modifikation af eukaryotiske celler
DE50010727D1 (de) Flächiges Implantat
DK1352895T3 (da) Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK0969846T3 (da) Sammensætninger og fremgangsmåder til reduktion af okulær hypertension
DK0969836T3 (da) Lactosefri, ikke-vandsugende og vandfri farmaceutiske sammensætninger af descarbethoxyloratadin
DK1114641T3 (da) Fluorethersammensætninger og metoder til inhibering af deres nedbrydning i nærværelse af en Lewis-syre
NO20021786L (no) Skumdempningsfremgangsmåter og sammensetninger
DK199800837A (da) Anlæg til behandling af emner
DK1355936T3 (da) Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
DE69936639D1 (de) Stimmprothese
DK1223887T3 (da) Implantatindstilling